



zymeworks

Zymeworks to Present at Wells Fargo Healthcare Conference

August 29, 2018

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA.

The Company will provide a corporate update and present upcoming catalysts on Wednesday, September 5, 2018 at 3:35 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks' lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20180829005038/en/): <https://www.businesswire.com/news/home/20180829005038/en/>

Zymeworks Inc.

Investor Inquiries:

Ryan Dercho, Ph.D., (604) 678-1388

[\[email protected\]](#)

or

Media Inquiries:

Angela Bitting, (925) 202-6211

[\[email protected\]](#)

Source: Zymeworks Inc.